Journals / Mikrobiyoloji Bülteni / 2009 / Cilt: 43 - Sayı: 2

Effect of linezolid in combination with isoniazid and rifambicin against multidrug resistant Mycobacterium tuberculosis clinical isolates

Çok ilaca dirençli Mycobacterium tuberculosis klinik izolatlarına karşı linezolidin izoniazid ve rifampisin ile kombine etkisi

Pages
293–297
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Although synergy was observed between linezolid and isoniazid just for one strain, further larger scale in vitro and in vivo studies are necessary to evaluate the effect of different drug combinations against multidrug-resistant M.tuberculosis strains.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Tuberculosis continues to be a serious public health problem worldwide.
📊
Key Findings & Data:This study was aimed to investigate the in vitro effect of linezolid alone and in combination with isoniazid and rifampicin against 10 multidrug resistant M.tuber culosis isolates by using the checkerboard method.
💡
Conclusion & Impact:Although synergy was observed between linezolid and isoniazid just for one strain, further larger scale in vitro and in vivo studies are necessary to evaluate the effect of different drug combinations against multidrug-resistant M.tuberculosis strains.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Antibiyotikler · antitüberküler · İlaç direnci

Abstract

Tuberculosis continues to be a serious public health problem worldwide. Since multi-drug resistant strains of Mycobacterium tuberculosis constitutes a serious problem in tuberculosis control, new and more effective chemotherapeutic agents are required. This study was aimed to investigate the in vitro effect of linezolid alone and in combination with isoniazid and rifampicin against 10 multidrug resistant M.tuber culosis isolates by using the checkerboard method. Checkerboard testing was performed by the broth microdilution method, using Middlebrook 7H9 broth with 10% oleic acid-albumin-dextrose-catalase. Antibiotic combinations were tested at concentrations of 0.06-4 |jg/ml for linezolid and 0.03-32 mg/ml for isoniazid and rifampicin. The results were evaluated according to the calculated fractional inhibitory concentration (FIC) index. All clinical isolates were found to be susceptible to linezolid; MICs of linezolid were 0.25 pg/ml for two strains and 0.5 pg/ml for the other strains. While rifampicin MIC values were > 32 Mg/ml for all the isolates, isoniazid MIC values were 4 ng/ml for two isolates, 8 pg/ml for six isolates, 16 Mg/ml for one isolate and 32 Mg/ml for one isolate. In this study, synergism was detected in only one strain between linezolid and isoniazid (FIC index: 0.265). Although synergy was observed between linezolid and isoniazid just for one strain, further larger scale in vitro and in vivo studies are necessary to evaluate the effect of different drug combinations against multidrug-resistant M.tuberculosis strains.

Özet

Tüberküloz dünyada ciddi bir sağlık problemi olmaya devam etmektedir. Çok ilaca dirençli Mycobacterium tuberculosis suşları tüberküloz kontrolü için çok ciddi problemler oluşturduğundan yeni ve daha etkili kemoterapötik ajanlara ihtiyaç vardır. Bu çalışmada, çok ilaca dirençli 10 M.tuberculosis klinik izolatına karşı linezolidin tek başına ve izoniazid ve rifampisin ilekombine etkilerinin dama tahtası (checkerboard) yöntemiyle in vitro olarak araştırılması amaçlanmıştır. Çalışmada, %10 oleik asit-albümin-dekstroz-katalaz içeren Middlebrook 7H9 buyyon kullanılarak mikrodilüsyon yöntemi uygulanmıştır. Antibiyotik kombinasyonları, linezolid için 4-0.06 pg/ml ve izoniazid ile rifampisin için 32-0.03 pg/ml konsantrasyonlarda test edilmiştir. Sonuçlar, fraksiyonel inhibisyon konsantrasyon (FİK) indeksi hesaplanarak değerlendirilmiştir. Çalışılan tüm klinik izolatlar linezolide duyarlı (2 izolat için MİK= 0.25 pg/ml, 8 izolat için MİK= 0.5 pg/ml) bulunmuştur. Rifampisin MİK değerleri tüm izolatlarda > 32 pg/ml iken, izoniazid MİK değerleri 2 izolat için 4 pg/ml, 6 izolat için 8 pg/ml ve birer izolat için 16 pg/ml ve 32 pg/ml olarak belirlenmiştir. Çalışmamızda, yalnızca bir izolat için linezolid ve izoniazid arasında sinerjistik etki saptanmış (FİK indeksi: 0.265), linezolid ve rifampisin kombinasyonunda sinerjistik etki bulunamamıştır. Sonuçlarımız, linezolid ile izoniazid (bir izolat hariç) ve rifampisin arasında sinerji olmadığını vurgulamakla birlikte daha fazla sayıda izolatı içeren ileri in vitro ve in vivo çalışmalara gereksinim olduğu açıktır.

🔖

Cite This Article

ÇOBAN, A. Y., BİLGİN, K., UZUN, M., DURUPINAR, B. (2009). Effect of linezolid in combination with isoniazid and rifambicin against multidrug resistant Mycobacterium tuberculosis clinical isolates. Mikrobiyoloji Bülteni, Cilt: 43 - Sayı: 2, 293–297. https://ajindex.com/articles/299368

References (13)

  1. Fattorini L, Tan D, Lona E, et al. Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice. Antimicrob Agents Chemother 2003; 47: 360-2
  2. Shoen CM, De Stefano MS, Sklaney MR, et al. Short-course treatment regimen to identify potential antitu- berculous agent in a murine model of tuberculosis. J Antimicrob Chemother 2004; 53: 641-5
  3. Bozdoğan B, Appelbaum PC. Oxazolidinones: activities, mode of action, and mechanisms of resistance. Int J Antimicrob Agents 2004; 23: 113-9
  4. Rodriguez JC, Ruiz M, Lopez M, et al. In vitro activity of moxifloxacin, levofloxacin, gatifoxacin and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents 2002; 20: 464-7
  5. Alcala L, Ruiz-Serrano Mj, Turegano CP, et al. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant first-line antituberculous drugs. Antimicrob Agents Chemother 2003; 47: 416-7
  6. Erturan Z, Uzun M. In vitro activity of linezolid against multidrug-resistant Mycobacterium tuberculosis isolates. Int J Antimicrob Agents 2005; 26: 78-80
  7. Tato M, de la Pedrosa EG, Canton R, et al. In vitro activity of linezolid against Mycobacterium tuberculosis complex, including multidrug-resistant Mycobacterium bovis isolates. Int J Antimicrob Agents 2006; 28: 75-8
  8. Koneman EW, Allen AD, Janda WM, Schreckenberger PC, Winn jr WC (eds). Antimicrobial Susceptibility Testing, pp: 841-4. In: Color Atlas and Textbook of Diagnostic Microbiology: 1997, 5th ed. Lippincott Co. Philadelphia
  9. Leite CQF, Berette ALRZ, Anno IS, et al. Standardization of broth microdilution method for Mycobacterium tuberculosis. Mem Inst Oswaldo Cruz 2000; 95: 127-9
  10. Çoban AY, Birinci A, Ekinci B, et al. Drug susceptibility testing of Mycobacterium tuberculosis by the broth microdilution method with 7H9 broth. Mem Inst Oswaldo Cruz 2004; 99: 111-3
  11. Rüsch-Gerdes S, Pfyffer GE, Casal M, et al. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 2006; 44: 688-92
  12. Richter E, Rüsch-Gerdes S, Hillemann D. First linezolid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2007; 51: 1534-6
  13. Sood R, Rao M, Singhal S, et al. Activity of RBx 7644 and RBx 8700, new inves